Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Mar 13, 2014, 08:20 ET

NEW YORK, March 13, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Northwest Biotherapeutics, Inc. Analyst Notes

On March 10, 2014, Northwest Biotherapeutics, Inc. (NW Bio) announced that the Paul Ehrlich Institute (PEI - the FDA of Germany) has approved the Company of a 'Hospital Exemption' early access program under Section 4b of the German Drug Law. According to NW Bio, under the exemption, it may provide DCVax-L, outside of the Company clinical trial and charge full price to patients for the treatment of any glioma brain cancers, both newly diagnosed and recurrent. NW Bio also stated that the German reimbursement authority (Institut Für Das Entgeltsystem Im Krankenhaus or InEK) has determined that DCVax-L treatments for glioma brain cancers are eligible to obtain reimbursement from the Sickness Funds (health insurers) of the German healthcare system. Commenting on the approval, Linda Powers, CEO of NW Bio, stated, "We are grateful to the PEI and InEK for these important decisions enabling DCVax-L to be made available to brain cancer patients now, and enabling reimbursement to be arranged with the Sickness Funds." The full analyst notes on Northwest Biotherapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/NWBO/report.pdf

La Jolla Pharmaceutical Co. Analyst Notes

On March 10, 2014, La Jolla Pharmaceutical Co. (La Jolla) announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease (CKD). According to La Jolla, the trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. According to the Company, GCS-100 was well tolerated and 117 out of the 121 patients enrolled, completed the treatment. Commenting on the results, George Tidmarsh, M.D., Ph.D., President and CEO of La Jolla, stated, "We want to thank the patients who volunteered for this study and our excellent group of investigators for their hard work completing this Phase 2 trial in a timely fashion. We are obviously delighted with the results. We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role." The full analyst notes on La Jolla Pharmaceutical Co. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/LJPC/report.pdf

Merrimack Pharmaceuticals, Inc. Analyst Notes

On March 10, 2014, Merrimack Pharmaceuticals, Inc.'s (Merrimack Pharmaceuticals) stock reflected an increase of 8.84% at $5.91. Over the past six months trading period, the Company's stock went up by 41.39%, compared to the Nasdaq Composite Index which went up by 16.95% during the same trading period. The full analyst notes on Merrimack Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/MACK/report.pdf

Rosetta Genomics, Ltd. Analyst Notes

On March 3, 2014, Rosetta Genomics, Ltd. (Rosetta Genomics) announced that data from a study of the Company's microRNA technology was published online in the American Journal of Cardiology in an article titled, "Relation of Reduced Expression of MiR-150 in Platelets to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure." According to the Company, the aim of the study was to evaluate the potential association of miRNAs in platelets with atrial fibrillation (AF) in patients with chronic systolic heart failure (HF). Kenneth A. Berlin, President and CEO of Rosetta Genomics, stated, "We are encouraged by the publication of these important data, which, along with our earlier study published in the European Journal of Heart Failure in 2012, support our continued research efforts in the area of blood-based microRNA biomarkers in order to advance new assays for the early diagnosis and refined risk stratification of heart failure patients. We plan to perform additional studies aimed at further examining the expression of identified miRNA biomarkers in various blood fractions and anticipate launching a new assay related to this area in 2017." The full analyst notes on Rosetta Genomics, Ltd. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/ROSG/report.pdf

IntelliPharmaCeutics International Inc. Analyst Notes

On March 4, 2014, IntelliPharmaCeutics International Inc. (Intellipharmaceutics) announced that it is scheduled to present at the 13th Annual Needham Healthcare Conference. According to the Company, the conference is scheduled at 3:00 p.m. EDT on April 8, 2014 at The Westin Grand Central Hotel, New York. Additionally, Intellipharmaceutics stated that the presentation will be made available via a live webcast and may be accessed through the Company's website under Investor Relations' Events and Presentations section. The full analyst notes on IntelliPharmaCeutics International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03132014/IPCI/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review